Evidence map›Paper›PMID 40860155›Full record

ArticleTheranostics2025

PTEN restoration and CXCR2 depletion synergistically enhance the effect of enzalutamide and inhibit bone metastatic CRPC.

Jiyuan Chen, Luyao Gong, Simeng Cao, Guanshan Song, Yeheng Peng, Yuanyuan Wang, Yan-Ru Lou, Teemu J Murtola, Yao Wu, Ganjun Yu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ANXA2-mediated Phagocytosis Generates ARAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiyuan ChenSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
Luyao GongSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
Simeng CaoSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
Guanshan SongShanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China.
Yeheng PengSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
Yuanyuan WangSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
Yan-Ru LouSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
Teemu J MurtolaTAYS Cancer Center, Department of Urology, Tampere University Hospital, Tampere 33100, Finland.
Yao WuSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
Ganjun YuNational Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China.
Yuan GaoSchool of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone NeoplasmsPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseReceptors, Interleukin-8BAnimalsBenzamidesCell Line, TumorCyclamsDiphosphonatesDrug Resistance, NeoplasmHumansMaleMiceNitrilesRNA, Small InterferingBenzamidesCyclamsDiphosphonatesenzalutamideNitrilesPhenylthiohydantoinPTEN PhosphohydrolasePTEN protein, humanReceptors, Interleukin-8BRNA, Small Interferingbone metastatic CRPCbone-targetingenzalutamidelipid nanoparticlesnucleic acid delivery

Identifiers

PMID40860155
PMCPMC12374621

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.